Editorial Comment on: “Ten-Year Experience with Percutaneous Cryoablation of Renal Tumors: Tumor Size Predicts Disease Progression” by Pickersgill et al.
Restricted accessResearch articleFirst published online December, 2020
Editorial Comment on: “Ten-Year Experience with Percutaneous Cryoablation of Renal Tumors: Tumor Size Predicts Disease Progression” by Pickersgill et al.
McIntoshAG, RistauBT, RuthK, et al.Active surveillance for localized renal masses: Tumor growth, delayed intervention rates, and >5-yr clinical outcomes. Eur Urol, 2018; 74:157–164.
2.
PierorazioPM, JohnsonMH, BallMW, et al.Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: The DISSRM registry. Eur Urol, 2015; 68:408–415.
3.
PickersgillNA, VetterJM, KimEH, et al.Ten-year experience with percutaneous cryoablation of renal tumors: Tumor size predicts disease progression. J Endourol, 2020; 34:1211–1217.
4.
SmaldoneMC, KutikovA, EglestonBL, et al.Small renal masses progressing to metastases under active surveillance. Cancer, 2012; 118:997–1006.
5.
ThompsonRH, AtwellT, SchmitG, et al.Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol, 2015; 67:252–259.
